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small. VMAT is a well suited technique with shorter 
treatment time but HT plans have better HI than VMAT.  
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Purpose or Objective: Dosimetric comparison among 
treatment plans from different RT techniques (photons, 
protons and carbon ions) within a prospective multicentric 
trial aiming at the evaluation of the impact of combined 
treatment modalities on target coverage and OARs sparing for 
sinonasal tumors. 
 
Material and Methods: High risk PTV (HR-PTV), which 
comprised gross disease, and low risk volume (LR-PTV), with 
elective neck, were defined for 5 pts. Four treatment plans 
were generated for each pt: a pure sequential (SEQ) and a 
pure SIB photon plan, a particle sequential plan with protons 
and carbon ion boost (p+C) and a combined plan with photons 
and carbon ion boost (ph+C). Prescription doses (PD) to HR-
PTV were 70 Gy (2 Gy/die) for photon plans and 75 GyE for 
plans with a carbon ion boost (21 GyE in 7 frs). PD to LR-PTV 
were 56 Gy (1.6 Gy/die) for SIB modality and 54 Gy (2 
Gy/die) for sequential plans. Varian Eclipse TPS was used to 
optimize VMAT photon plans with coplanar and non-coplanar 
arcs. Particle plans were calculated using Siemens Syngo TPS 
and IMPT optimization strategy. The highest priority during 
optimization was given to spare neurological structures, 
followed by PTVs coverage and then remaining OARs. A 
dedicated software (VODCA, MSS Medical Software Solution 
GmbH, Switzerland) was used to sum up photon and particle 
plans and to compare DVHs from different approaches. We 
considered different parameters: the most significant for 
PTVs coverage were volume encompassed by 70 Gy isodose 
(V70Gy), conformity index and homogeneity index. As for 
OARs, V10Gy was reported for temporal lobes, brain and 
mean dose (Dmean) for contra-lateral optic nerve, chiasm, 
cord, brainstem, cochleae. Integral dose was recorded to 
evaluate healthy tissue (HT, patient volume minus larger 
PTV). Differences in techniques were analyzed by paired 
Student’s 2-sided t-tests for each dosimetric parameter, 
taking p-value <0.05 as statistically significant. 
 
Results: All plans could be considered clinically acceptable. 
The photon ones showed a better conformality and 
homogeneity for HR-PTV against p+C plans. Although 
minimum dose (as percentage of PD) was higher for photon 
plans, V70Gy was statistically relevant in favor of p+C plans 
vs the other modalities. Despite a higher PD for plans with 
carbon ion boost, a significant advantage on some OARs was 
recorded: Dmean in p+C plans was significantly lower for 
contra-lateral optic nerve, chiasm and cochleae, as it is 
V10Gy for temporal lobes and brain. This finding was 
reinforced by a statistically significant difference in integral 
dose for p+C plans vs the others, but also for ph+C plans vs 
SIB. See averaged DVHs in Fig. 1. 
 
 
 
Conclusion: Although less homogeneous and conformed, 
particle plans allow a higher PD to HR-PTV compared to 
photons. Due to their specific physical characteristics, 
combined particle treatments can potentially better spare 
OARs and HT in terms of intermediate and low doses. 
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Purpose or Objective: To allow or not the patient transfer 
between 2 energy-matched Linacs, differing only by their 
MLC generation, in case of breakdown. 
 
Material and Methods: Two linacs were beforehand matched 
in terms of energy (TPR20,10) and each separate calculation 
model in the TPS validated. This retrospective comparison 
was performed with the calculated dose from the TPS to 
assess the impact of transferring a patient from one machine 
to another, for some fractions (n=1 to 5) over the whole 
treatment (N fractions). One should note that 3D plan 
verification failed in general if the measurements occurs on 
the wrong machine. 
Fifty VMAT plans were studied (head & neck , whole brain, 
rectum, prostate, other; 10 plans of each), corresponding to 
60 PTVs and 100 OARs. Dose was re-computed with the non-
planned machine, without any optimization, if up to n=5 
fractions are transferred. 
Reported dose-metrics (see ICRU-83) are Dmean (mean dose), 
Dmax (max dose), D95% and HI (homogeneity index) for all 
ROIs, and well-known parameters are used for some OARs, 
depending of OAR type (V20, V74,...). Each parameter is 
expressed as relative to the initial planned treatment. 
 
Results: There is a systematic over-dose delivering when 
transferring a patient from the “new generation” Linac 
(Mnew) to the “old” one (Mold). The opposite is checked. 
Dmean and Dmax variations are linearly dependent of the 
number of transferred fractions (R²=0.91), for PTVs and 
OARs. No linear correlation could be found for others 
metrics, which seem to strongly depend on each anatomy. 
Variations are always more important for OARs than for PTVs. 
The maximum difference was found as the Dmean on a right 
femur for a rectum treatment (11.4%). This value is increased 
to 15% and set as the maximum available for n=5. 
 
Conclusion: Dose differences are here mainly due to 
thickness variations of MLC leaves, over other design 
improvements (leaf profiles, rounded leaf ends,...), as dose 
variation is related to leaf thickness and OARs are on the 
other hand more affected by linac transfer than PTVs 
(protected ROIs are more often under leaves than targets). 
